Kimberly Burk
Nurse Practitioner · Newburgh, INNPI 1588335756
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 65.1% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $19,222, more than ten times the $1,796 reported in 2022. Among nurse practitioner clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 581 payments — averaging $46.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Livanova USA, Inc.$2K
- Eisai Inc.$876
- UCB, Inc.$875
- Pfizer$729
- Lundbeck LLC$598
- plus $4K from 27 others
What the payments were for
- Speaking & faculty fees$14,06352%
- Travel & lodging$1,2365%
- Food & beverage$11,57943%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 222 | $17,507 |
| Livanova USA, Inc. | 14 | $2,373 |
| Eisai Inc. | 35 | $876 |
| UCB, Inc. | 41 | $875 |
| Pfizer | 60 | $729 |
| Lundbeck LLC | 39 | $598 |
| Teva Pharmaceuticals USA, Inc. | 29 | $562 |
| AstraZeneca | 10 | $527 |
| Catalyst Pharmaceuticals, Inc. | 18 | $456 |
| Neurelis, Inc. | 20 | $366 |
| Jazz Pharmaceuticals Inc. | 12 | $299 |
| Lilly USA, LLC | 15 | $292 |
| SK Life Science, Inc. | 13 | $269 |
| Amgen | 6 | $166 |
| Argenx US, Inc. | 5 | $137 |
| Axsome Therapeutics, Inc. | 5 | $116 |
| Sumitomo Pharma America, Inc. | 7 | $115 |
| Novartis | 6 | $109 |
| Genentech USA, Inc. | 4 | $70 |
| TG Therapeutics, Inc. | 3 | $69 |
| Acadia Pharmaceuticals Inc | 3 | $65 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Medtronic | 1 | $23 |
| Bristol Myers Squibb | 1 | $23 |
| Baxter Healthcare | 1 | $22 |
| Biogen | 1 | $20 |
| Cala Health, Inc. | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Aucta Pharmaceuticals, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$10,550
- UBRELVY$3,870
- VNS Therapy$1,479
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$524
- ULTOMIRIS$123
- VYEPTI$123
How this compares
$26,878 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 20 | $168,094 |
| QuliptaAtogepant | 125 | $159,205 |
| Nurtec OdtRimegepant Sulfate | 91 | $124,119 |
| UbrelvyUbrogepant | 80 | $105,608 |
| Emgality PenGalcanezumab-Gnlm | 94 | $77,013 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $25,597 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 14 | $12,610 |
| Ajovy SyringeFremanezumab-Vfrm | 12 | $8,615 |
| Sumatriptan Succinate | 35 | $7,152 |
| Memantine Hcl | 108 | $3,551 |
| Carbamazepine ErCarbamazepine | 12 | $3,447 |
| Levetiracetam | 101 | $3,070 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 116 | $2,280 |
| Donepezil Hcl | 238 | $2,164 |
| Primidone | 32 | $1,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $17,507 | $264,813205 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $562 | $168,09420 claims |
| PfizerNurtec Odt | $729 | $124,11991 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Newburgh
- Shannon KratzerNewburgh$12K
- Elise SchuttNewburgh$10K
- Jordyn NovsekNewburgh$9K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.